Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Functional expression of the single subunit nadh dehydrogenase in mitochondria in vivo: A potential therapy for complex i deficiencies

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Seo, B. B.
  • Nakamaru-Ogiso, E.
  • Cruz, P.
  • Flotte, T. R.
  • Yagi, Takao
  • Matsuno-Yagi, A.

publication date

  • September 2004

journal

  • Human Gene Therapy  Journal

abstract

  • It has been reported that defects of mitochondrial proton-translocating NADH-quinone oxidoreductase (complex I) are involved in many human diseases (such as encephalomyopathies and sporadic Parkinson's disease). However, no effective remedies have been established for complex I deficiencies. We have adopted a gene therapy approach utilizing the NDI1 gene that codes for the single subunit NADH dehydrogenase of Saccharomyces cerevisiae (Ndi1). Our earlier experiments show that the Ndi1 protein can replace or supplement the functionality of complex I in various cultured cells. For this approach to be useful, it is important to demonstrate in vivo that the mature protein is correctly placed in mitochondria. In this study, we have attempted in vivo expression of the NDI1 gene in skeletal muscles and brains (substantia nigra and striatum) of rodents. In all tissues tested, the Ndi1 protein was identified in the injected area by immunohistochemical staining at 1-2 weeks after the injection. Sustained expression was observed for at least 7 months. Double-staining of the sections using antibodies against Ndi1 and F(1)-ATPase revealed that the expressed Ndi1 protein was predominantly localized to mitochondria. In addition, the tissue cells expressing the Ndi1 protein stimulated the NADH dehydrogenase activity, suggesting that the expressed Ndi1 is functionally active. It was also confirmed that the Ndi1 expression induced no inflammatory response in the tissues examined. The data indicate that the NDI1 gene will be a promising therapeutic tool in the treatment of encephalomyopathies and neurodegenerative diseases caused by complex I impairments.

subject areas

  • Animals
  • Brain
  • Dependovirus
  • Electron Transport Complex I
  • Female
  • Genetic Therapy
  • Immunochemistry
  • Inflammation
  • Male
  • Mice
  • Mitochondria
  • Mitochondrial Encephalomyopathies
  • Muscle, Skeletal
  • NADH Dehydrogenase
  • Parkinson Disease
  • Protein Subunits
  • Proton-Translocating ATPases
  • Rats
  • Saccharomyces cerevisiae
  • Saccharomyces cerevisiae Proteins
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1043-0342

Digital Object Identifier (DOI)

  • 10.1089/1043034041839217

PubMed ID

  • 15353043
scroll to property group menus

Additional Document Info

start page

  • 887

end page

  • 895

volume

  • 15

issue

  • 9

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support